Phaseline

Companies › Chengdu CoenBiotech

Chengdu CoenBiotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EEC
Recombinant Mycobacterium tuberculosis fusion protein for tuberculosis infection diagnosis
–Phase 3Tuberculosis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07152639EECPhase 3TuberculosisInfectious diseaseMay 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Biofabri Vedanta Biosciences Novavax Valneva Austria Osivax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.